LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 310

Search options

  1. Article ; Online: Anti-Epidermal Growth Factor Receptor Maintenance Therapy in Metastatic Colorectal Cancer-Another Piece to the Puzzle.

    Morano, Federica / Pietrantonio, Filippo

    JAMA network open

    2023  Volume 6, Issue 9, Page(s) e2333488

    MeSH term(s) Humans ; Colonic Neoplasms ; Rectal Neoplasms ; Receptors, Growth Factor
    Chemical Substances Receptors, Growth Factor
    Language English
    Publishing date 2023-09-05
    Publishing country United States
    Document type Journal Article ; Comment
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2023.33488
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: New options for late-line treatment of metastatic colorectal cancer.

    Lonardi, Sara / Pietrantonio, Filippo

    Nature reviews. Gastroenterology & hepatology

    2023  Volume 21, Issue 2, Page(s) 76–77

    MeSH term(s) Humans ; Colorectal Neoplasms/therapy ; Antibodies, Monoclonal/therapeutic use ; Rectal Neoplasms ; Intestine, Large ; Antineoplastic Combined Chemotherapy Protocols
    Chemical Substances Antibodies, Monoclonal
    Language English
    Publishing date 2023-12-06
    Publishing country England
    Document type Journal Article
    ZDB-ID 2493722-8
    ISSN 1759-5053 ; 1759-5045
    ISSN (online) 1759-5053
    ISSN 1759-5045
    DOI 10.1038/s41575-023-00881-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

    Pietrantonio, Filippo

    The New England journal of medicine

    2020  Volume 382, Issue 9, Page(s) 876–877

    MeSH term(s) Benzimidazoles ; Carbamates ; Cetuximab ; Colorectal Neoplasms ; Humans ; Proto-Oncogene Proteins B-raf ; Sulfonamides
    Chemical Substances Benzimidazoles ; Carbamates ; Sulfonamides ; binimetinib (181R97MR71) ; encorafenib (8L7891MRB6) ; BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Cetuximab (PQX0D8J21J)
    Language English
    Publishing date 2020-03-03
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc1915676
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer.

    Randon, Giovanni / Pietrantonio, Filippo

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2023  Volume 29, Issue 20, Page(s) 4021–4023

    Abstract: Overexpression of the EGFR ligands amphiregulin (AREG)/epiregulin (EREG) may be a surrogate of EGFR dependency regardless of sidedness in metastatic colorectal cancer. High AREG/EREG may be coupled with negative hyper-selection (i.e., lack of genomic ... ...

    Abstract Overexpression of the EGFR ligands amphiregulin (AREG)/epiregulin (EREG) may be a surrogate of EGFR dependency regardless of sidedness in metastatic colorectal cancer. High AREG/EREG may be coupled with negative hyper-selection (i.e., lack of genomic drivers of primary resistance beyond RAS and BRAF) to identify patients with right-sided tumors and potential sensitivity to EGFR blockade. See related article by Williams et al., p. 4153.
    MeSH term(s) Humans ; Amphiregulin/genetics ; Epiregulin/genetics ; Multiomics ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; ErbB Receptors/genetics ; Intercellular Signaling Peptides and Proteins ; Colonic Neoplasms ; Rectal Neoplasms ; Antibodies ; Artificial Intelligence
    Chemical Substances Amphiregulin ; Epiregulin ; ErbB Receptors (EC 2.7.10.1) ; Intercellular Signaling Peptides and Proteins ; Antibodies ; EGFR protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2023-09-05
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-23-1954
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma-Reply.

    Zhao, Joseph J / Pietrantonio, Filippo / Sundar, Raghav

    JAMA oncology

    2023  Volume 9, Issue 7, Page(s) 1005–1006

    MeSH term(s) Humans ; Esophageal Squamous Cell Carcinoma/drug therapy ; Immune Checkpoint Inhibitors/adverse effects ; Esophageal Neoplasms/drug therapy ; Carcinoma, Squamous Cell/drug therapy ; Antineoplastic Combined Chemotherapy Protocols
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2023-06-07
    Publishing country United States
    Document type Letter ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2023.0975
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Trattamento con FOLFIRI e aflibercept in paziente con metastasi epatiche potenzialmente resecabili di adenocarcinoma del colon sinistro RAS e BRAF wild-type, dopo terapia adiuvante a base di oxaliplatino.

    Pietrantonio, Filippo

    Recenti progressi in medicina

    2018  Volume 109, Issue 11, Page(s) 24e–26e

    Abstract: This is a "best practice" case report of a non-uncommon clinical scenario, referring to an early liver relapse, judged as technically resectable, following adjuvant oxaliplatin-based treatment for left-sided, RAS and BRAF wild-type colon cancer. The ... ...

    Title translation Perioperative treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, left-sided colon cancer, with early relapse following adjuvant oxaliplatin- based treatment due to potentially resectable liver metastases.
    Abstract This is a "best practice" case report of a non-uncommon clinical scenario, referring to an early liver relapse, judged as technically resectable, following adjuvant oxaliplatin-based treatment for left-sided, RAS and BRAF wild-type colon cancer. The choice of aflibercept vs cetuximab/panitumumab relies on the need to counteract an aggressive disease, without loosing the chance of radical surgery, nor loosing treatment options in the third-line setting. Treatment decisions are evidence-based on efficacy data of neoadjuvant anti-angiogenic treatment, as well as on the detrimental effect derived from the addition of cetuximab to perioperative chemotherapy.
    MeSH term(s) Angiogenesis Inhibitors/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/pathology ; Colonic Neoplasms/surgery ; Female ; Fluorouracil/administration & dosage ; Humans ; Leucovorin/administration & dosage ; Liver Neoplasms/pathology ; Liver Neoplasms/secondary ; Liver Neoplasms/surgery ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Recurrence, Local ; Oxaliplatin/administration & dosage ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins p21(ras)/genetics ; Receptors, Vascular Endothelial Growth Factor/administration & dosage ; Recombinant Fusion Proteins/administration & dosage
    Chemical Substances Angiogenesis Inhibitors ; Recombinant Fusion Proteins ; Oxaliplatin (04ZR38536J) ; aflibercept (15C2VL427D) ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1) ; BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT) ; Camptothecin (XT3Z54Z28A)
    Language Italian
    Publishing date 2018-12-18
    Publishing country Italy
    Document type Case Reports ; Journal Article
    ZDB-ID 138266-4
    ISSN 2038-1840 ; 0034-1193
    ISSN (online) 2038-1840
    ISSN 0034-1193
    DOI 10.1701/3031.30303
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Trattamento di seconda linea con FOLFIRI e aflibercept in paziente con adenocarcinoma del colon destro avanzato e BRAF mutato.

    Pietrantonio, Filippo

    Recenti progressi in medicina

    2018  Volume 109, Issue 11, Page(s) 27e–29e

    Abstract: This is the case report of a woman with more than 70 years and good PS, with diagnosis of right sided, BRAF mutated and MSI-high colon cancer, diffusively metastatic to lymph nodes. The treatment sequencing of FOLFOXIRI bevacizumab (I line) and FOLFIRI ... ...

    Title translation Second-line treatment with FOLFIRI plus aflibercept in a patient with right-sided, BRAF mutated metastatic colon cancer.
    Abstract This is the case report of a woman with more than 70 years and good PS, with diagnosis of right sided, BRAF mutated and MSI-high colon cancer, diffusively metastatic to lymph nodes. The treatment sequencing of FOLFOXIRI bevacizumab (I line) and FOLFIRI aflibercept (II line) allowed to maximally shrink the disease burden and dramatically extend survival thanks to the treatments' intensification (due to BRAF mutation-related aggressiveness) and the immune-modulating effects of anti-angiogenic treatments (due to immune-suppressive burden associated with MSI-high status).
    MeSH term(s) Aged ; Angiogenesis Inhibitors/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/genetics ; Colonic Neoplasms/pathology ; Female ; Fluorouracil/administration & dosage ; Humans ; Leucovorin/administration & dosage ; Lymphatic Metastasis ; Mutation ; Proto-Oncogene Proteins B-raf/genetics ; Receptors, Vascular Endothelial Growth Factor/administration & dosage ; Recombinant Fusion Proteins/administration & dosage
    Chemical Substances Angiogenesis Inhibitors ; Recombinant Fusion Proteins ; aflibercept (15C2VL427D) ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1) ; BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT) ; Camptothecin (XT3Z54Z28A)
    Language Italian
    Publishing date 2018-12-18
    Publishing country Italy
    Document type Case Reports ; Journal Article
    ZDB-ID 138266-4
    ISSN 2038-1840 ; 0034-1193
    ISSN (online) 2038-1840
    ISSN 0034-1193
    DOI 10.1701/3031.30304
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Trattamento con FOLFIRI e aflibercept in paziente con adenocarcinoma del colon destro RAS e BRAF wild-type e metastasi epatiche potenzialmente resecabili.

    Pietrantonio, Filippo

    Recenti progressi in medicina

    2018  Volume 109, Issue 11, Page(s) 20e–23e

    Abstract: This is the case report of a patient with right-sided, RAS and BRAF wild-type metastatic colorectal cancer, with borderline/potentially resectable liver-limited disease. Following neoadjuvant treatment with FOLFOX plus bevacizumab and radical resection, ... ...

    Title translation Treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, right-sided colon cancer and potentially resectable liver metastases.
    Abstract This is the case report of a patient with right-sided, RAS and BRAF wild-type metastatic colorectal cancer, with borderline/potentially resectable liver-limited disease. Following neoadjuvant treatment with FOLFOX plus bevacizumab and radical resection, an early intra-hepatic disease relapse was observed and deemed as potentially resectable. Therefore, treatment with FOLFIRI plus aflibercept was started: a major partial response and radical re-resection were achieved. Following unresectable disease relapse, second-line treatment with FOLFIRI aflibercept was resumed and achieved again a partial response that is still ongoing after more than 9 months. This case report highlights how treatment goals (potentially curative resection vs palliation), molecular status and primary tumor location influence treatment strategies in order to maximize patients' outcomes.
    MeSH term(s) Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Adenocarcinoma/surgery ; Adult ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/pathology ; Colonic Neoplasms/surgery ; Fluorouracil/administration & dosage ; Humans ; Leucovorin/administration & dosage ; Liver Neoplasms/secondary ; Liver Neoplasms/surgery ; Male ; Organoplatinum Compounds/administration & dosage ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins p21(ras)/genetics ; Receptors, Vascular Endothelial Growth Factor/administration & dosage ; Recombinant Fusion Proteins/administration & dosage ; Treatment Outcome
    Chemical Substances Organoplatinum Compounds ; Recombinant Fusion Proteins ; aflibercept (15C2VL427D) ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1) ; BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT) ; Camptothecin (XT3Z54Z28A)
    Language Italian
    Publishing date 2018-12-18
    Publishing country Italy
    Document type Case Reports ; Journal Article
    ZDB-ID 138266-4
    ISSN 2038-1840 ; 0034-1193
    ISSN (online) 2038-1840
    ISSN 0034-1193
    DOI 10.1701/3031.30302
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality.

    Antoniotti, Carlotta / Pietrantonio, Filippo / Corallo, Salvatore / De Braud, Filippo / Falcone, Alfredo / Cremolini, Chiara

    JCO precision oncology

    2022  Volume 3, Page(s) 1–14

    Language English
    Publishing date 2022-01-31
    Publishing country United States
    Document type Journal Article
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.18.00397
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Caring for Patients With Cancer During the COVID-19 Outbreak in Italy.

    Pietrantonio, Filippo / Garassino, Marina Chiara

    JAMA oncology

    2020  Volume 6, Issue 6, Page(s) 821–822

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus ; Coronavirus Infections ; Humans ; Italy ; Neoplasms ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-04-10
    Publishing country United States
    Document type Journal Article ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2020.1426
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top